Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy Volunteer
In brief
The study is designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy Japanese subjects at increasing doses given for 7 days in order to allow for including Japanese subjects in future global studies. A cohort of Caucasian subjects will be included in the study to evaluate cardiac effects, assessed by digital ECGs (dECG) recordings, also in Caucasian subjects.
Key facts
- Study ID
- NCT02176252
- Run by
- Ardelyx
- People needed
- 83
- Starts
- 2013-07-01
- Expected to finish
- 2013-12-01
- Last updated by the study team
- 2014-06-27
Who can join
Age: 19 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Healthy man or woman
- Body mass index between 18 and 29.9 kg/m2, inclusive
You may not qualify if…
- Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the gastrointestinal (GI) tract
- Any surgery on the small intestine or colon, excluding appendectomy
- Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, metabolic, endocrine, neurologic, psychiatric disease, or any condition that may interfere with the subject successfully completing the trial or that would present a safety risk to the subject.
Where it is running
- WCCT Global — Cypress, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.